SCHEMBL57177

SCHEMBL57177

NC(CCP(=O)(O)OCc1cccc(CC(=O)O)c1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.47
GRM4 Q14833 6/20 0.46
GRM8 O00222 4/20 0.46
GRM6 O15303 2/20 0.46
FOLH1 Q04609 1/20 0.45
CETP P11597 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL55394 0.88 FOLH1 (0.49) GRM4GRM8GRM6FOLH1CETP
SCHEMBL56051 0.87 FOLH1 (0.46) GRM4GRM8GRM6FOLH1CETP
SCHEMBL56343 0.85 GRM4 (0.57) SLC7A5GRM4GRM8GRM6FOLH1
SCHEMBL21189181 0.83 GRM4 (0.46) SLC7A5GRM4GRM8GRM6
SCHEMBL56061 0.78 GRM4 (0.58) GRM4GRM8GRM6FOLH1CETP
SCHEMBL56601 0.77 SLC1A5 (0.46) GRM4GRM8GRM6FOLH1CETP
SCHEMBL57236 0.76 GRM8 (0.62) GRM4GRM8GRM6CETP
SCHEMBL21189162 0.75 SLC7A5 (0.44) SLC7A5GRM4GRM8GRM6
SCHEMBL21189163 0.75 SLC7A5 (0.44) SLC7A5GRM4GRM8GRM6
SCHEMBL21189140 0.75 SLC7A5 (0.44) SLC7A5GRM4GRM8GRM6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008137446-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASE TRUSTEES OF BOSTON UNIVERSITY (US) 2008-11-13 WO claimed
EP-4291301-A1 NON-INVASIVE CANCER TREATMENT Scientia Biotech S.L. (ES) 2023-12-20 EP disclosed
WO-2022171826-A1 NON-INVASIVE CANCER TREATMENT SCIENTIA BIOTECH S.L (ES) 2022-08-18 WO disclosed
EP-4043071-A1 NON-INVASIVE CANCER TREATMENT Scientia Biotech S.L. (ES) 2022-08-17 EP disclosed
US-11179348-B2 Combination comprising pterostilbene for the treatment of cancer FUNDACIÓN UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR (ES) 2021-11-23 US disclosed
EP-3368025-A1 COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER Fundación Universidad Católica de Valencia San Vicente Mártir (ES) 2018-09-05 EP disclosed
US-20180214390-A1 COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER UNIVERSITAT DE VALÈNCIA - ESTUDI GENERAL (ES) 2018-08-02 US disclosed
WO-2017012774-A1 COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER FUNDACIÓN UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR (ES) 2017-01-26 WO disclosed
US-8129557-B2 Phosphonic acid diester derivative and method for producing thereof Nagai, Kazuhiro (JP) 2012-03-06 US disclosed
US-20090163725-A1 PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF HIRATAKE, GOU (JP) 2009-06-25 US disclosed
WO-2008137446-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASE TRUSTEES OF BOSTON UNIVERSITY (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180214390-A1 COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER GSTP1, GGT1, GSTA1 SLC7A5 866/4885GRM4 1140/4885GRM8 1178/4885
US-20090163725-A1 PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF PPA1, G6PD, PHOSPHO1 SLC7A5 3382/4885GRM4 4122/4885GRM8 4595/4885
US-11179348-B2 Combination comprising pterostilbene for the treatment of cancer GSTP1, GGT1, GSTA1 SLC7A5 866/4885GRM4 1140/4885GRM8 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.